NTLA - Intellia Therapeutics, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.99
|
Rev Est: $12.2M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.38
DETAILS
HIGH:
$48.00
LOW:
$7.00
MEDIAN:
$14.50
CONSENSUS:
$19.38
UPSIDE:
42.71%
Market Cap:
1.57B
Volume:
2,840,727
Avg Volume:
4,632,481
52 Week Range:
5.9-28.25
Sector:
Healthcare
Industry:
Biotechnology
Beta:
2.11
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
403
IPO Date:
2016-05-06
EPS (TTM):
-5.25
P/E Ratio:
-2.22
Revenue (TTM):
57.88M
Total Assets:
1.19B
Total Debt:
210.20M
Cash & Equiv:
189.18M
Rev Growth (5Y):
6.1%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-49.5%
Debt/Equity:
0.24
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.92 | $-1.02 | +9.8% | $13.8M | $12.2M | +13.2% |
| 2025-08-07 | $-0.99 | $-1.03 | +3.9% | $14.2M | $14.1M | +1.3% |
| 2025-05-08 | $-1.10 | $-1.26 | +12.7% | $16.6M | $11.9M | +39.3% |
| 2025-02-27 | $-1.24 | $-1.32 | +6.1% | $12.9M | $10.9M | +18.5% |
| 2024-11-07 | $-1.34 | $-1.37 | +2.2% | $9.1M | $8.9M | +2.3% |
| 2024-08-08 | $-1.31 | $-1.21 | -8.3% | $7.0M | $19.2M | -63.7% |
| 2024-05-09 | $-1.06 | $-1.35 | +21.5% | $28.9M | $11.5M | +151.6% |
| 2024-02-22 | $-1.46 | $-1.47 | +0.7% | $1.9M | $12.8M | -85.1% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.88M | 36.27M | 52.12M | 33.05M | 57.99M | 43.10M | 30.43M | 26.12M | 16.48M | 6.04M | 0 |
| Net Income | (519.02M) | (481.19M) | (474.19M) | (267.89M) | (134.23M) | (99.53M) | (85.34M) | (67.54M) | (31.63M) | (12.40M) | (14.31M) |
| EPS | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | -1.96 | -1.98 | -1.88 | -0.91 | -0.70 | -1.39 |
| Total Assets | 1.19B | 1.30B | 1.52B | 1.29B | 676.32M | 334.28M | 347.31M | 376.24M | 298.97M | 82.14M | 10.69M |
| Total Debt | 210.20M | 115.35M | 130.70M | 74.02M | 39.30M | 18.38M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 189.18M | 226.75M | 523.51M | 123.41M | 160.02M | 57.23M | 58.86M | 340.68M | 273.06M | 75.82M | 9.85M |
| Operating Cash Flow | (348.88M) | (394.09M) | (333.29M) | (225.03M) | (49.91M) | (103.24M) | (61.26M) | (65.28M) | 36.11M | (1.76M) | (3.48M) |
| Free Cash Flow | (354.66M) | (408.07M) | (391.68M) | (237.79M) | (53.50M) | (110.03M) | (67.61M) | (75.37M) | 29.94M | (4.32M) | (3.90M) |
| FCF per Share | -3.59 | -4.60 | -5.09 | -3.35 | -0.96 | -2.33 | -1.57 | -2.09 | 0.87 | -0.24 | -0.38 |
| Book Value | 871.96M | 1.05B | 1.24B | 1.04B | 527.07M | 269.88M | 277.92M | 300.60M | 209.84M | 67.36M | 7.57M |
| Cash & ST Investments | 601.51M | 912.22M | 1.19B | 748.69M | 597.37M | 279.73M | 314.06M | 340.68M | 273.06M | 75.82M | 9.85M |
| ROC Equity | -0.60 | -0.46 | -0.38 | -0.26 | -0.25 | -0.37 | -0.31 | -0.22 | -0.15 | -0.18 | -1.89 |